Phase 3 N=114 Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage.o
Abortion, Spontaneous · Abortion in First Trimester · Pain Uterus
Primary: Pain With Cervical Dilation — 52; 45 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=88 Substance Use Treatment and Recovery Team (START)
Opioid-use Disorder · Opioid-Related Disorders · Alcohol Use Disorder
Primary: Number of Patients With In-hospital Initiation of Medication for OUD or AUD — 22; 9 Participants — p=<.001
N/A N=489 ACCESS (Access for Cancer Caregivers for Education and Support for Shared Decision Making)
Cancer · Pain
Primary: Change in Generalized Anxiety Disorder- 7 — 7.73; 8.81; 8.42; 7.06 score on a scale
N/A N=30 Fathering In Recovery
Parenting · Opioid-use Disorder · Father-Child Relations
Primary: Parenting Practices Interview — 2.84; 3.83 score on a scale — p=<0.001
Phase 2 N=89 Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
Dry Eye Disease · Dry Eye Syndrome
Primary: Number of Participants With Adverse Events by Severity in Each Cohort — 0; 0; 2; 0 Participants
Phase 3 N=793 Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
Prostatic Neoplasms
Primary: Overall Survival (OS) — 15.8; 14.6 Months — p=0.2616
Phase 3 N=109 tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
Pulmonary Embolism
Primary: Efficacy: RV/LV Ratio Difference — 1.66; 1.10; -0.56 RV/LV Ratio
Early Phase 1 N=1,012 Virtual cOaching in Making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)
Elder Abuse
Primary: Implementation in Terms of Participation — 1012 Participants
Phase 2 N=51 Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer
Cognitive Decline · Chemo-brain
Primary: Change in Visual Working Memory - Delayed Matching to Sample Test — 16; 13; 16 Participants
N/A N=320 Small Financial Incentives to Promote Smoking Cessation
Smoking Cessation
Primary: Biochemically-verified Smoking Cessation — 22; 14 Participants
Phase 2 N=29 PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant
Hematologic Malignancy
Primary: The Number of Patients With GVHD/Relapse-free (GRFS) Survival — 25 Participants
Early Phase 1 N=92 CYP3A4 Activity and Mineral Homeostasis
Vitamin D and Calcium Homeostasis
Primary: 1, 25(OH) D3 Vitamin D — 3.2; 1.7; 3.7; -3.3 pM — p=0.884
N/A N=112 Vitamin D Oral Replacement in Asthma
Asthma · Vitamin D Deficiency · Pediatric Obesity
Primary: Part 1: Optimal Dosing Level to Use in Part 2 — 8000; 50000 IU
Phase 2 N=106 A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial Hypertension
Primary: Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks — -27.6; -168.4; -258.9; 802.0 dynes*sec/cm^5 — p=0.0030
N/A N=8 Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy
Primary Progressive Aphasia · PPA
Primary: Change in Accuracy of Naming Trained Verbs (0 to 15, Higher Scores Reflect Better Naming Abilities) as Assessed by Object and Action Naming Battery (OANB) — 2.3; 2.05…